HS
MCRB icon

HighVista Strategies’s Seres Therapeutics MCRB Stock Holding History

HighVista Strategies’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,238
Closed -$1.07M – 133
2021
Q2 		$1.07M Buy
+2,238
New +$944K 0.76% 20

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HighVista Strategies's MCRB Position: Q3 2021 in Review

HighVista Strategies sold out of Seres Therapeutics (MCRB) in Q3 2021, closing a stake of 2,238 shares — an estimated $1.07M sold.

HighVista Strategies first reported a position in MCRB in Q2 2021 and held it in 1 quarter. The position peaked at $1.07M in Q2 2021. 133 funds tracked by Wall St. Rank hold MCRB as of Q3 2021.

  • HighVista Strategies reported no remaining Seres Therapeutics position as of Q3 2021 after selling out during the quarter.
  • HighVista Strategies sold 2,238 Seres Therapeutics shares in Q3 2021, an estimated $1.07M.
  • HighVista Strategies first reported a position in Seres Therapeutics in Q2 2021 and held it in 1 quarter.
  • HighVista Strategies's Seres Therapeutics position peaked at $1.07M in Q2 2021.
  • 133 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2021.

Based on HighVista Strategies's 13F filing for Q3 2021, filed 15 Nov 2021.